- PAN1
Trial Status
Completed
Cancer Type
Pancreatic Cancer
Protocol Title
A randomised phase II study evaluating potential predictive biomarkers in the treatment of locally advanced and metastatic pancreatic cancer.
Purpose of the Study
The AGITG PAN1 trial was designed to assess whether a biomarker called hENT1 might be useful for selecting treatments for patients with advanced pancreatic cancer who would respond well to gemcitabine chemotherapy treatment.
The PAN1 study Trial Management Committee recommended closure of the study to further randomization, effective from Friday the 22nd of February 2013, following a decision by the funders to cease support for the study.
Principal Investigator
Dr Yu Jo Chua
Funding
Avner Nahmani Foundation
DETAILED INFORMATION AVAILABLE
Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR), please click here
Trial Status
Completed
Cancer Type
Pancreatic Cancer
Conference Presentation Reference
- Chua YJ, Karapetis CS, Gebski V, O’Connell R, Begbie S, Nott LM, Cronk MF, Underhill C, Abdi EA, Van Hagen T, Wong N, Hall M, Ferraro DA, Sjoquist KM, Santos C, Mackey JR, Goldstein D. Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil and leucovorin) treated patients with metastatic pancreatic cancer: the randomized phase II PAN1 study. Gastrointestinal Cancers Symposium; 16–18 Jan 2014; San Francisco.
- Chua Y, Karapetis C, Underhill C, Nott L, Goldstein D, Cronk M, Gebski V, Wong N, Sjoquist K, Biankin A. PAN1: a randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago. Abstract TPS4137
Aim
To prospectively evaluate hENT1 as a predictive marker of benefit from gemcitabine treatment in locally advanced and metastatic pancreatic cancer.
Summary
The PAN1 study Trial Management Committee recommended closure of the study to further randomization, effective from Friday the 22nd of February 2013, following a decision by the funders to cease support for the study.
Principal Investigator
Dr Yu Jo Chua
Funding
Avner Nahmani Foundation
Changing outcomes for people with gastro-intestinal cancer since 1991